SAN DIEGO --(BUSINESS WIRE)--Aug. 14, 2023-- Biocept, Inc . (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS
SAN DIEGO --(BUSINESS WIRE)--Aug. 14, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
SAN DIEGO --(BUSINESS WIRE)--Aug. 25, 2023-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023 , beginning at 4:00 p.m. Eastern time ( 1:00 p.m. Pacific time ) to provide a business update and to answer questions. Participants can pre-register for the conference
SAN DIEGO --(BUSINESS WIRE)--Sep. 5, 2023-- Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25 th Annual Global Investment Conference being held
SAN DIEGO --(BUSINESS WIRE)--Sep. 8, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the
SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal
